Customer No. 20,995

Docket No.: DAVI257.003APC

INFORMATION DISCLOSURE STATEMENT

Applicant

Hart et al.

App. No

10/538,393

Filed

June 8, 2005

For

IN VITRO IMMUNIZATION

Examiner

Unknown

Art Unit

1636

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 10 references to be considered by the Examiner. Also enclosed are 10 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: _1/31/07

By:

Raymond D. Smith Registration No. 55,634

Agent of Record

Customer No. 20,995

(805) 547-5580

IDS 3340340 012307

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Filing Date June 8, 2005

First Named Inventor Hart et al.

Art Unit 1636

Examiner Unknown

10/538,393

(Multiple sheets used when necessary)
SHEET 1 OF 1

Attorney Docket No. DAVI257.003APC

	U.S. PATENT DOCUMENTS								
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear				

Application No.

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	т¹		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	1	International Search Report for International Application No. PCT/AU2003/001647, filed December 9, 2003.	
	2	CHO, H-I et al. 2001 "Generation of cytotoxic T lymphocytes specific for human cytomegalovirus using dendritic cells in vitro" J Immunotherapy 24 :242-249.	
	3	HOFFMANN, TK et al. 2000 "Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells" Cancer Research 60:3542-3549.	
	4	ITO, A et al. 2001 "Generation of hepatitis C virus-specific cytotoxic T lymphocytes from healthy individuals with peptide-pulsed dendritic cells" <i>J Gastroenterology and Hepatology</i> 16 :309-316.	
	5	RE, F et al. (November 16, 2002) "Green fluorescent protein (GFP) expression in dendritic cells enhances their immunogenicity and elicits GFP-specific cytotoxic T-cell (CTL) responses in humans" Blood 100(11) pp. Abstract No. 2663, Whole Abstract.	
	6	PEGGS K et al. 2001 "Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions" <i>Blood</i> 97 :994-1000.	
	7	PEGGS, K et al. 2002 "Characterization of human cytomegalovirus peptide-specific CD8 ⁺ T-cell repertoire diversity following <i>in vitro</i> restimulation by antigen-pulsed dendritic cells" <i>Blood</i> 99 :213-223.	
	8	PÉREZ-DÍEZ, A. et al. 1998 "Generation of CD8 ⁺ and CD4 ⁺ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene" Cancer Research 58 :5305-5309.	
	9	SZMANIA, S. et al. 2001 "Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers" <i>Blood</i> 98 :505-512.	
	10	VERFUERTH, S et al. (November 16, 2000) "A versatile culture system for the <i>in vitro</i> expansion of autologous donor-derived cytomegalovirus, Epstein Barr virus and Aspergillus antigen-specific T cells" <i>Blood</i> 96 (11, part 1) pp. 27a, Abstract No. 103, Whole Abstract.	

3340214 012307

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.